Evidence map›Paper›PMID 41429590›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2026

Plasma Proteomics Identifies Thousand-and-One-Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target.

Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun and 6 more

Abstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pengfei XinGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wenzhen LiShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Fudan University, Shanghai, China.
Xinyu AGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jun ShenGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaohui MengWuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi, China.
Yanqin BianGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Haihui HanWuxi Affiliated Hospital of Nanjing University of Chinese Medicine, Wuxi, China.
Zheng XiangGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Lei RanGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Songtao SunGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jun XieGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Tao YueGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qi ZhuGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaoming ZhangNational Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China.
Lu XieShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Fudan University, Shanghai, China.ORCID 0000-0001-7541-2243
Lianbo XiaoGuanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0001-9305-0776

Funding

the Changning National Master of Traditional Chinese Medicine Studiothe National Natural Science Foundation of China 82474302the Shanghai Science and Technology Commission Support Project 23Y11921900
6 · The paper itself

Abstract

objectiveBone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted therapy.

methodsData-independent acquisition mass spectrometry was used for proteomic quantification and bioinformatic analysis on plasma samples from 160 patients with RA and 40 healthy controls. Key proteins associated with bone destruction were screened by integrating Sharp scores with synovial single-cell RNA sequencing data and subsequently validated in two independent cohorts (N

resultsA total of 4,998 plasma proteins were identified, with 506 showing significant differential expression between active and remitted RA. Thousand-and-one-amino acid kinase 3 (TAOK3) levels were positively associated with Sharp scores and markedly elevated in patients with active RA. Combining TAOK3 with C-reactive protein improved diagnostic accuracy for active RA (area under the curve = 0.915). High TAOK3 expression was also associated with increased relapse frequency. Functional studies showed that TAOK3 knockdown suppressed the tumor-like phenotype of FLSs and down-regulated matrix metalloproteinase 1/2/3 and cathepsin K, whereas TAOK3 overexpression promoted pannus cell-mediated bone erosion, mitigated by TAOK3-targeted inhibitor. In vivo, its inhibition showed therapeutic effects in CIA mice.

conclusionTAOK3 serves as a potential biomarker for bone destruction in active RA and as a therapeutic target for precision monitoring and intervention.

Indexed as

Arthritis, RheumatoidAdultAnimalsArthritis, ExperimentalBiomarkersCase-Control StudiesC-Reactive ProteinFemaleHumansMaleMiceMice, Inbred DBAMiddle AgedProteomicsSynoviocytesBiomarkersC-Reactive Protein

Identifiers

PMID41429590
PMCPMC13129648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.